These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 29260582)

  • 1. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
    Handy CE; Antonarakis ES
    Future Oncol; 2018 Apr; 14(10):907-917. PubMed ID: 29260582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sipuleucel-T for the treatment of advanced prostate cancer.
    Frohlich MW
    Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
    Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND
    Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
    Garcia JA; Dreicer R
    Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.
    Holko P; Kawalec P
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):63-73. PubMed ID: 24224852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
    Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current role of immunotherapy for the treatment of prostate cancer.
    Porfyris O; Kalomoiris P
    J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Kantoff PW; Higano CS; Shore ND; Berger ER; Small EJ; Penson DF; Redfern CH; Ferrari AC; Dreicer R; Sims RB; Xu Y; Frohlich MW; Schellhammer PF;
    N Engl J Med; 2010 Jul; 363(5):411-22. PubMed ID: 20818862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
    Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
    Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
    Laccetti AL; Subudhi SK
    Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
    Dawson NA; Roesch EE
    Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sipuleucel-T: in metastatic castration-resistant prostate cancer.
    Plosker GL
    Drugs; 2011 Jan; 71(1):101-8. PubMed ID: 21175243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Huber ML; Haynes L; Parker C; Iversen P
    J Natl Cancer Inst; 2012 Feb; 104(4):273-9. PubMed ID: 22232132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sipuleucel-T: Prototype for development of anti-tumor vaccines.
    Carballido E; Fishman M
    Curr Oncol Rep; 2011 Apr; 13(2):112-9. PubMed ID: 21243538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.